Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing

Valeant Pharmaceuticals Intl (NYSE: VRX)

$11.18 USD $0.50 (4.68%)
Last Price $11.18
Net Change $0.5 (4.68%)
Bid $0
Ask Price $0
Open Price $10.68
Previous Close Price $10.68
High Price $11.43
Low Price $10.67
Number of Trades 62,304
Volume 27,044,420
Fifty Two Week High $38.5 (2016-05-03)
Fifty Two Week Low $10.35 (2017-03-21)
Average Daily Volume 18,960,160
Share Outstanding 347,840 Shares
Total Dividend Payout 0/yr
Dividend Yield 0%
1st Quarter Earnings $1.26 (2017-02-28)
2nd Quarter Earnings $1.55 (2016-11-08)
3nd Quarter Earnings $1.4 (2016-08-09)
4th Quarter Earnings $1.27 (2016-06-07)
PE Ratio $1.95
EPS Growth $-27.26
Recent Earnings $1.26
Annual EPS $5.48
Last Quarter EPS $
Market Capitalization $3.89B
Insider Shareholders % 0.1637%
Annual Revenue $0B
No. Shares Outstanding 347,840
Inst. Shareholder % 57.53%
Annual Net Income $-2.41B
TTM Net Profit Margin $-24.9
1-Year Return -58.7%
3-Year Return -91.52%
5-Year Return -79.61%
5-Year Revenue Growth 292.7%
5-Year Earnings Growth 100.37%
5-Year Dividend Growth 0%
Annual Dividend $0
Annual Dividend Yield 0%
Change in EPS YTD -27.26%
Dividends per Share $1
Stock Split Ratio 2-1
Beta -0.2
Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant's development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.

Today's Valeant Pharmaceuticals Stock Update

While we usually like to analyze for investors whether a stock is a buy or not, we also like to give you a quick rundown of the Valeant Pharmaceuticals stock information you need today, with key data on recent VRX moves. That's what you can get right here. VRX shares rose 4.68% or $0.50 from the previous trading session. That took the Valeant Pharmaceuticals stock price to $11.18. So where does that put Valeant Pharmaceuticals stock relative to the past year of prices? The Valeant Pharmaceuticals stock price is at a lower price than it was last year at this time, with the stock price lower by 61.26%.

BREAKING: How a 26(f) Program Can Save Your Retirement

The Valeant Pharmaceuticals stock price 52-week high is $38.50. That was hit on 5/03/2016. The VRX stock 52-week low is $10.35, reached on 3/21/2017. Another number to note - VRX trading volume yesterday was 8,421,500. That's less than Valeant Pharmaceuticals stock's average daily trading volume of 27,044,420. Valeant Pharmaceuticals's market capitalization - the amount of shares outstanding times the share price - is 3,888,851,000. That gives Valeant Pharmaceuticals a mid-size market cap, because it's been 2 billion and 10 billion. As of the start of April 2016, Apple has the biggest market cap of all publicly traded companies.

TRENDING: The Best Stocks to Buy Now

The current P/E (price/earnings) ratio of Valeant Pharmaceuticals stock is 1.97. That's lower than the March 2016 S&P 500 P/E ratio of about 23. To really gauge if this stock's P/E is high or low, you should compare VRX to other companies in the same industry. The current EPS (earnings per share) of VRX is -6.92. Beta - how closely the stock trades with the overall market, with a beta of 1 meaning it trades in step with the broader index -- for Valeant Pharmaceuticals is -0.20. Valeant Pharmaceuticals stock does not pay a dividend right now. Generally a dividend yield of 2% or more is decent for those investors who want income from dividend stocks. Every day we publish Valeant Pharmaceuticals stock news and coverage on a handful of other key stocks we're watching now so you can maximize profits. To get new info and stock news on VRX and other companies you are interested in, sign up for Money Morning - it's free.

UP NEXT: These Are the Top 5 Marijuana Stocks to Watch in 2017 - Don't Miss This Sector's Staggering Profit Potential

Click here to read more stories